A new treatment combination for Helicobacter pylori — a common stomach bacterium linked to ulcers and gastritis — based on a domestically developed drug has shown comparable, and in some cases superior, efficacy in eradicating the infection compared with standard therapy, according to recent clinical research.
The therapy offers a promising new approach to tackling the growing challenge of antimicrobial resistance, said the study published in the international journal The Lancet Infectious Diseases in late September.
The experimental triple therapy centres on rifasutenizol, a novel antimicrobial agent developed specifically for H. pylori infection by Tennor Therapeutics, a pharmaceutical company based in Suzhou, Jiangsu province.
SANGHA KOMMUNE (SSR) 